Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark.

de Luise C, Lanes SF, Jacobsen J, Pedersen L, Sørensen HT.

Eur J Epidemiol. 2007;22(4):267-72. Epub 2007 Mar 7.

PMID:
17342451
2.

Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence.

Salpeter SR.

Drugs. 2009 Oct 22;69(15):2025-33. doi: 10.2165/11318580-000000000-00000.

PMID:
19791824
3.

Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database.

Jara M, Lanes SF, Wentworth C 3rd, May C, Kesten S.

Drug Saf. 2007;30(12):1151-60.

PMID:
18035867
4.

Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.

Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS.

Arch Intern Med. 2009 Aug 10;169(15):1403-10. doi: 10.1001/archinternmed.2009.233. Erratum in: Arch Intern Med. 2009 Sep 28;169(17):1568.

PMID:
19667304
5.

Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD.

Verhamme KM, Afonso AS, van Noord C, Haag MD, Koudstaal PJ, Brusselle GG, Sturkenboom MC.

Pulm Pharmacol Ther. 2012 Feb;25(1):19-26. doi: 10.1016/j.pupt.2011.10.004. Epub 2011 Oct 21.

PMID:
22051450
6.

Pooled clinical trial analysis of tiotropium safety.

Kesten S, Jara M, Wentworth C, Lanes S.

Chest. 2006 Dec;130(6):1695-703.

PMID:
17166984
7.

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.

Chong J, Karner C, Poole P.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009157. doi: 10.1002/14651858.CD009157.pub2. Review.

PMID:
22972134
8.

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.

Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.

PMID:
17310045
9.

Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease.

Gershon AS, Wang L, To T, Luo J, Upshur RE.

COPD. 2008 Aug;5(4):229-34. doi: 10.1080/15412550802237507.

PMID:
18671148
10.

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S.

Ann Intern Med. 2005 Sep 6;143(5):317-26.

PMID:
16144890
11.

Cardiovascular safety of tiotropium in patients with COPD.

Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP.

Chest. 2010 Jan;137(1):20-30. doi: 10.1378/chest.09-0011. Epub 2009 Jul 10.

PMID:
19592475
12.

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.

Cheyne L, Irvin-Sellers MJ, White J.

Cochrane Database Syst Rev. 2015 Sep 22;(9):CD009552. doi: 10.1002/14651858.CD009552.pub3. Review.

PMID:
26391969
13.

Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.

Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM.

Respir Med. 2007 Jul;101(7):1398-405. Epub 2007 Mar 23.

14.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
15.

Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis.

Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA.

Respir Med. 2009 Oct;103(10):1421-9. doi: 10.1016/j.rmed.2009.05.020. Epub 2009 Jun 24. Review.

16.

A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD.

Hilleman DE, Malesker MA, Morrow LE, Schuller D.

Int J Chron Obstruct Pulmon Dis. 2009;4:253-63. Epub 2009 Jul 20. Review.

17.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators.

N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

18.

Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.

Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG, Sturkenboom MC.

Eur Respir J. 2013 Sep;42(3):606-15. doi: 10.1183/09031936.00005813. Epub 2013 Mar 21.

19.

Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.

Singh S, Loke YK, Enright P, Furberg CD.

Postgrad Med J. 2014 Apr;90(1062):205-7. doi: 10.1136/postgradmedj-2011-201275rep.

PMID:
24643260
20.

A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.

Kern DM, Williams SA, Tunceli O, Wessman C, Zhou S, Pethick N, Elhefni H, Trudo F.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 18;9:775-83. doi: 10.2147/COPD.S64491. eCollection 2014.

Supplemental Content

Support Center